Wells Fargo analyst Larry Biegelsen raised the firm’s price target on Bausch + Lomb (BLCO) to $26 from $23 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 sales/EBITDA ahead of expectations and raised guidance on both metrics. Wells believes there is positive momentum into Q4 and 2025 behind most of the segments, strong Miebo uptake, and turnaround in Xiidra.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb price target raised to $23 from $22 at H.C. Wainwright
- Bausch + Lomb Sees Strong Growth in Q3 2024
- Bausch + Lomb reports Q3 adjusted EPS 17c, consensus 22c
- Bausch + Lomb raises FY24 revenue view to $4.73B-$4.83B from $4.7B-$4.8B
- Bausch Health price target raised to $10 from $8.50 at RBC Capital